SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 92 filers reported holding SPERO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $662 | -23.0% | 547,165 | -7.8% | 0.00% | 0.0% |
| Q2 2023 | $860 | +44.5% | 593,431 | +44.6% | 0.00% | 0.0% |
| Q1 2023 | $595 | +0.3% | 410,300 | +19.7% | 0.00% | 0.0% |
| Q4 2022 | $593 | -99.9% | 342,900 | +59.7% | 0.00% | 0.0% |
| Q3 2022 | $429,000 | -38.4% | 214,700 | -77.1% | 0.00% | 0.0% |
| Q2 2022 | $696,000 | -26.7% | 939,017 | +760.7% | 0.00% | 0.0% |
| Q1 2022 | $949,000 | -44.5% | 109,100 | -28.8% | 0.00% | -50.0% |
| Q3 2020 | $1,710,000 | -61.7% | 153,203 | -53.6% | 0.00% | -50.0% |
| Q2 2020 | $4,464,000 | +70.4% | 329,903 | +1.7% | 0.00% | +33.3% |
| Q1 2020 | $2,620,000 | -19.4% | 324,303 | -4.1% | 0.00% | +50.0% |
| Q4 2019 | $3,252,000 | +21.3% | 338,203 | +33.8% | 0.00% | 0.0% |
| Q3 2019 | $2,680,000 | +8.3% | 252,803 | +17.6% | 0.00% | 0.0% |
| Q2 2019 | $2,474,000 | +70.5% | 214,903 | +89.7% | 0.00% | +100.0% |
| Q1 2019 | $1,451,000 | +449.6% | 113,303 | +164.1% | 0.00% | – |
| Q4 2018 | $264,000 | +109.5% | 42,903 | +257.5% | 0.00% | – |
| Q3 2018 | $126,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
| Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
| OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
| Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
| Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
| Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
| AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
| DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
| Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
| XTX Topco Ltd | 58,368 | $70,625 | 0.01% |